French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorized for use in the EU. The tumor-reducing drug is aimed at patients with the second most common form of skin cancer — cutaneous squamous cell carcinoma (CSCC) — whose cancer is advanced, and who are not candidates for surgery or radiation therapy. […] The US Food and Drug Administration (FDA) approved Libtayo in September 2018, while Health Canada gave it the conditional green light earlier this month. …